

Cell Reports Medicine, Volume 4

Supplemental information

**Targeting neoadjuvant chemotherapy-induced
metabolic reprogramming in pancreatic cancer
promotes anti-tumor immunity and chemo-response**

Rong Tang, Jin Xu, Wei Wang, Qingcai Meng, Chenghao Shao, Yiyin Zhang, Yubin Lei, Zifeng Zhang, Yuan Liu, Qiong Du, Xiangjie Sun, Di Wu, Chen Liang, Jie Hua, Bo Zhang, Xianjun Yu, Si Shi, and Chinese Study Group for Pancreatic Cancer

1 **Supplemental Information**

2
3 **Targeting Neoadjuvant Chemotherapy-induced Metabolic Reprogramming in Pancreatic Cancer Promotes**
4 **Anti-Tumor Immunity and Chemo-response.**

5
6 **Authors:** Rong Tang,^{1,2,#} Jin Xu,^{1,2,#} Wei Wang,^{3,4,#} Qingcai Meng,^{1,2,#} Chenghao Shao,⁵ Yiyin Zhang,⁶ Yubin Lei,⁷
7 Zifeng Zhang,^{1,2} Yuan Liu,^{2, 8} Qiong Du,^{2, 9} Xiangjie Sun,^{2, 10} Di Wu,^{3,4} Chen Liang,^{1,2} Jie Hua,^{1,2} Bo Zhang,^{1,2}
8 Xianjun Yu,^{1,2,*} Si Shi,^{3,4,11,*} Chinese Study Group for Pancreatic Cancer

9 **Affiliations:**

10 ¹Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

11 ²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

12 ³Shanghai Pancreatic Cancer Institute, Shanghai, China.

13 ⁴Pancreatic Cancer Institute, Fudan University, Shanghai, China.

14 ⁵Department of Pancreatic-Biliary Surgery, Second Affiliated Hospital of Naval Medical University, Shanghai,
15 China.

16 ⁶Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou,
17 Zhejiang Province, China.

18 ⁷Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences,
19 Westlake University, Hangzhou, Zhejiang Province, China.

20 ⁸Department of Endoscopy, Fudan University Shanghai Cancer Center, Shanghai, China.


21 ⁹Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.

22 ¹⁰Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

23 [#]These authors contributed equally.

24 ¹¹Lead contact

25
26 *Correspondence: shisi@fudanpci.org (S. S.), yuxianjun@fudan.edu.cn (X. Y.)



31

32 **Figure S1. NAC promoted the expression of genes associated with prolonged survival. Related to Figure 1.**










33 (A) IHC staining showed the percentage of Ki67+ malignant cells were significantly decreased in PDAC samples

34 that treated with NAC, analyzed by unpaired t test (Mean with standard deviation) (N=54). (B) Three dimensional

35 PCA for NAC and UR PDAC samples based on the differentially expressed genes. (C) Genes upregulated in NAC


36 samples (screened by Wilcoxon test) were associated with prolonged survival interval. (D) The percentage of

37 deregulated genes associated with better or poor prognosis of PDAC.



39 **Figure S2. Functional annotations and enrichment analysis for genes differentially expressed between NAC**
40 **and UR samples. Related to Figure 1 and Table S4-9.**

41 (A-B) Functional enrichment analyses for all detected proteins in PDAC samples, GO and KEGG annotation,
42 respectively. (C) KEGG analysis for proteins upregulated in NAC group (D) IPR enrichment predicted the function
43 of proteins upregulated in NAC group based on the domain structure. (E) GO enrichment for genes upregulated in
44 NAC group. (F) KEGG enrichment for genes downregulated in NAC group. (G) KEGG enrichment for genes
45 upregulated in NAC group. (H) GSEA for the activity alteration of mitotic cytokinetic process, basal transcription
46 factor, nucleotide salvage and nucleosome positioning between NAC and UR groups. (I) Pearson correlational
47 analysis showed the expression pattern between transcriptome and proteome in PDACs showed high consistency.




48


49 **Figure S3. Single-cell and spatial clustering for PDACs with and without NAC. Related to Figure 2 and**
50 **Figure 3.**

51 (A) UMAP plot showed sequenced cells could be divided into 100 subclusters based on initial clustering. (B) UMAP
52 analysis showed the distribution of cells from samples with and without NAC. (C) The mRNA expression of CD8A
53 in T cells between NAC and UR groups. (D) T cells are featured more clonotype expansion in samples with NAC
54 (Mean with standard deviation). (E) ssGSEA algorithm showed increased CD8+T cell infiltration in samples with
55 NAC based on t test (Mean with standard deviation). (F) Spatially resolved mapping of cell identity markers for

56 sequenced cells.




58 **Figure S4. NAC reshaped PDAC immune microenvironment. Related to Figure 2 and Figure 3.**
59 (A) Three independent algorithms supported more CD8+ T cells infiltrated in PDACs which underwent NAC. (B)
60 Heatmap showed differentially activated immune signatures between NAC and UR PDAC samples. (C) Scatter plot
61 showed upregulation trend for protein level of granzymes in PDACs which underwent NAC with marginal
62 significance. (D) The infiltration of Treg cells had no differences between samples treated with NAC and UR. Left
63 panel: representative mIF graph showed the positive staining of Treg cell (N=20). (E) IHC staining showed CD163+
64 cells infiltrated less in PDACs treated with NAC (N=54). (F-G) B cells and CD4 cells had an increased infiltration
65 in NAC samples, which were based on TIMER and EPIC algorithm, respectively. (H) Demo picture of TLS
66 selection using IHC staining. (I) The density of TLSs was higher in PDACs treated with NAC (N=54). (J) PDAC
67 samples which underwent NAC had an increased immunophenoscore. (K) The expression level of common immune
68 checkpoints had no significant differences between samples treated with NAC and UR. The statistical significance
69 shown in this figure was detected using the t test. Error bars manifested Mean with standard deviation.



70
 71 **Figure S5. The metabolic reprogramming of PDAC cells is associated with the alteration of immune**
 72 **parameters. Related to Figure 4.**
 73 (A) UMAP analysis showed ductal cells could be divided into two major clusters based on the expression of FXYD2
 74 and FXYD3. (B) The presentation of markers for different subclusters of ductal cells. (C) The activity differences of
 75 metabolic pathways between ductal cells from samples treated with and without NAC (Mean with Mean with
 76 standard deviation). (D) UMAP plot showed that PDAC cells could be classified into four subclusters based on their
 77 metabolic activity. (E) Fold change of intensity for C1 to C4 signatures between the MA of NAC and UR samples.
 78 (F) The correlation between deregulated metabolism-associated genes and CD8⁺ T cells' infiltration, which was
 79 estimated by multiple algorithms. The deregulated metabolism-associated genes were identified by analyzing the
 80 differentially expressed genes between pancreatic ductal cells from PDAC samples with and without NAC. (G) IHC
 81 staining showed decreased expression of LDHA in samples received NAC (N=54). Left panel: Representative graph


82 for positive staining of LDHA in PDAC. (H) Proteome and transcriptome data validated the downregulation trend of
 83 LDHA in NAC samples. (I) IHC staining showed an inversed trend in terms of the pattern of LDHA expression and
 84 CD8+ T cell infiltration in PDAC samples with and without NAC. (J) The mRNA expression level of LDHA and
 85 CD8A were negatively correlated in NAC samples, instead of UR PDACs (K). The correlation between LDHA and
 86 CD8A was insignificant in UR PDACs of TCGA dataset. The statistical significance shown in this figure was
 87 detected using the t test. Correlational analyses were performed by Pearson approach.



88
 89 **Figure S6. NAC induced metabolome alteration between PDACs with and without NAC. Related to Figure 4**
 90 **and Figure 5.**

91 (A) Heatmap showed metabolites' abundance was distinct between PDACs with and without NAC. VIP is a
 92 statistical measure used to assess the importance of metabolites in multivariate analysis. (B-D) Bray–Curtis NMDS,
 93 PCoA and PCA algorithms supported that the difference of metabolome could distinguish NAC and UR PDACs. (E)

94 A heatmap showed the differences of metabolites in the anaerobic glycolysis, glutamine metabolism, fatty acid
95 utilization and oxidative phosphorylation pathways between NAC and UR samples, which were identified using
96 untargeted metabolome. (F) Spatial-resolved metabolome revealed region-specific metabolic patterns in PDAC. (G)
97 Representative graph of mIF staining showed the distribution of CD8+ T cells in different regions with metabolic
98 difference. (H) PG_38:5 was significantly upregulated in cluster_7 regions compared to cluster_5 regions. (I)
99 Ideograph showed the procedures for T cell separation and stimulation of metabolites. (J) Heatmap panel showed the
100 differentially enriched metabolites and their relevance with treatment states. ROC curves panel showed the accuracy
101 for the metabolites to distinguish different treatment states. (K) Most NAC-induced metabolites promoted T cell
102 function except for oleic acid, which impaired the secretion of cytokines of T cells (N=3). (L) Neutralizing CD36
103 significantly restrained the chemoresistance induced by oleic acid treatment in pancreatic cancer cells. (M) Western
104 blot validation for the knockdown efficiency of CD36 in panc-1 cells. (N) CCK-8 results showed that knockdown of
105 CD36 blocked the effect of oleic acid on panc-1 cell proliferation (N=5). (O) Oleic acid addition increased the
106 viability of panc-1 cell with AG treatment for 24 hours in CD36-intact condition (N=5).



107

108 **Figure S7. PDAC upregulated CD36 expression after NAC. Related to Figure 6.**

109 (A) Proteome sequencing showed CD36 expression was upregulated in PDAC samples that treated with NAC. (B)
 110 Venn plot showed CD36 was the only metabolic membrane protein that upregulated after NAC. (C) Flowcytometry
 111 showed CD36 was upregulated in peripheral myeloid-linkage cells. (D) CD8+ T cells treated with lysate from NAC
 112 samples showed higher IFN- γ secretion compared to UR samples. (E) CD8+ T cells treated with lysate from NAC
 113 samples showed higher cytotoxic performance compared to UR samples, showed by LDH-releasing experiments.

114 (F) CD8+ T cells treated with lysate from NAC samples with low CD36 expression showed higher cytotoxic
115 performance compared to NAC samples with high CD36 expression, showed by LDH-releasing experiments. (G)
116 CD36 expression in lysate was negatively correlated with LDH releasing level, showed by spearman correlational
117 analysis. (H) TSNE analysis for labeled cell clusters of murine PDAC immune infiltrates by flowcytometry. (I)
118 CD36 had increased distribution on myeloid-linkage cells in harvested murine PDAC after AG treatment. (J)
119 Combination of CD36 blockage and AG synergistically enhanced the expression level of immune-related molecules
120 in murine PDAC (N=5). (K) CD36 expression was more important for pancreatic cancer cells that showed resistance
121 to gemcitabine (based on DepMap database). The statistical significance shown in this figure was detected using t
122 test. Error bars manifested Mean with standard deviation.
123

124
125

Table S1. Characteristics for patients with Proteotranscriptomic sequencing. Related to Figure 1.

Treatment	NAC(N=56)	UR(N=37)
Age at diagnosis (year)		
Mean	58.38	61.22
Range	39-72	43-77
Gender		
Female	30	19
Male	26	18
Tumor location		
Head	19	19
Body-tail	36	17
Multiple site	1	1
Differentiation		
Well	3	0
Well-Moderate	7	5
Moderate	31	22
Moderate-Poor	12	9
Poor	3	1
Lymphovascular invasion		
yes	19	7
no	37	30
Perineural invasion		
yes	49	36
no	7	1

126 **Table S10. Clinical information of samples used for scRNA-seq. Related to Figure 2.**
 127

128

Sample	Gender	Age	Location	Perineural invasion	Vascular invasion	Neoadjuvant
NAC2	Female	66	Neck	+	+	Yes
UR3	Male	49	Head	+	+	No
NAC7	Female	67	Body-tail	-	-	Yes
NAC5	Male	61	Body-tail	+	+	Yes
NAC1	Male	67	Body-tail	-	+	Yes
UR1	Female	70	Body-tail	-	+	No
NAC6	Female	70	Body-tail	-	+	Yes
NAC4	Male	68	Body-tail	+	+	Yes
UR2	Female	51	Head	+	+	No
NAC3	Male	72	Body-tail	-	+	Yes
NAC8	Female	69	Head	-	+	Yes

129

130 **Table S13. Summary of clinical information for PDAC samples in tissue microarray. Related to Figure 6.**
 131

	CD36-Low	CD36-high 132
Number of patients	128	150
Age (year)		
<=60	54	61
>60	74	89
Gender		
Male	74	89
Female	54	61
Tumor location		
Head	72	81
Body/tail	56	69
T Stage		
T1-2	115	98
T3	35	30
N stage		
N0-1	112	127
N2	16	23
Number of patients with adjuvant AG	32	27
Vascular tumor thrombus		
Yes	40	57
No	88	93
Perineural invasion		
Yes	113	141
No	15	9